
Harnessing zero‑party data: Transforming pharma advertising ...
Integrating zero-party data into ads, pharma and healthcare brands can revolutionise how they engage with patients
Newsletters and Deep Dive digital magazine
Integrating zero-party data into ads, pharma and healthcare brands can revolutionise how they engage with patients
AstraZeneca is celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to its top-seller Tagrisso.
Amgen has bagged a second indication for its B cell-depleting therapy Uplizna after the FDA cleared it for rare inflammatory disease IgG4-RD.
Bid on used pharmaceutical production and packaging equipment. View auction April 22-24.
Germany has agreed to reimburse CSL Behring's haemophilia B gene therapy Hemgenix with a 'unique' outcomes-based payment model.
Editor's Picks
Newsletters and Deep Dive
digital magazine